RE:Let's call a spade a spadeThe problem I see with such a low 3 years back SP is that any deal of importance can become hard to do as why not buy the whole company?.
If the big shareholders does not support the SP, it could go under a dollar and then become an easier target for a takeover by one of the pharma interested in a deal with Prometic. and of course, even the 3 billionnaires and big shareholders wait to support the SP until they think the floor price is almost touch to get the cheapest shares price possible. These guys have the tools and the people to analyse all of this and take advantage of the lowest price possible. There not to help anyone but themselfs.
It is a sure thing that there are some pharma in discussion with Prometic for one or some indication. The managment is telling the market for a while now that there are discussion.
Obviously, these discussion takes a long time as the big players are sharks and want a deal that is at there advantage. That is why Pierre does not come with a deal as he don't want to give away the whole company for some upfront cash.
These company monitor Prometic advancment and obviously share market performance.
With such a low SP, Prometic has less and less leverage to get a deal signed in there favor even if the science progress. Furthermore, the progress in the science and Pg BLA makes it even more atrative for an hostile takeover at this low Share price.
The FDA will come up with feedback on a timeline in september after the inspection of the facility end of august. They should also come up with a response for the pediatric designation in the same time. This will bring back confidence.
Until then, I see no Deal considering the above and shorts will continue there game until the big shareholder decide (with there high profile adviser team) that it is time to jump in supporting the SP and grabbing the cheapest share possible.